According to the Global Cancer Observatory (GLOBOCAN), in 2018, cervical cancer was the fourth most common type of cancer worldwide in women of all ages. The overall number of cases was 569 847, while this type of cancer was the cause of death in the 311 365 women (1). The interesting fact is that incidence of cervical carcinoma is two to four times higher in low- and middle-income countries (2, 3), which is the consequence of the lack of adequate and more efficient therapies and vaccines, as well as novel training opportunities for medical personnel.
In the majority of cases, cervical carcinoma is due to infection with double-stranded DNA (dsDNA) human papillomavirus (HPV) from the Papovaviridae family. HPV types are divided into the two groups according to the carcinogenic features, low-risk and high-risk types of virus. High-risk types are present in 99.7% (4) of cases of cervical carcinoma, with the two most virulent genotypes, HPV16 and 18 (5). The use of HPV vaccines is the most important way of preventing the disease caused by infection with certain high-risk types of HPV.
Commercially available HPV vaccines are Cervarix, a bivalent vaccine (HPV16 and HPV18), Gardasil, a tetravalent vaccine (HPV 6, HPV11, HPV16, and HPV18), and Gardasil 9, a nonavalent vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) (6). Besides vaccines, organizing and developing cervical cancer prevention screening programs is equally important. Prevention strategies vary between countries and also depend on socioeconomic status. High-income countries have well developed screening programs which include cytological smear screening. The establishment of the Pap smear cytology tests has led to a reduction in cervical cancer incidence and mortality in the United States of 83% (6, 7).
The standard procedure which is being done during the radical hysterectomy in early-stage cervical carcinoma is pelvic lymph node dissection (PLND) (10). This procedure is used for determining the status of pelvic lymph nodes to check if metastasis exists. The main disadvantage and adverse effects of PLND is the potential occurrence of lymphedema in the lower abdomen and lower extremities (11). Besides, those women who experience lymphedema may develop emotional problems such as depression and anxiety (10, 12). Therefore, PLND is increasingly being replaced with less-radical sentinel lymph node biopsy (SLN) to decrease the risk of lymphoedema as the severe lifelong morbidity (9).
SLN biopsy is recommended by new European Society of Gynecological Oncology (ESGO), European Society for Radiotherapy and Oncology (ESTRO), and European Society of Pathology (ESP) guidelines, as well as by the National Comprehensive Cancer Network (NCCN) guidelines as an alternative method for lymph node staging (13, 14). Detecting the SLN involves injecting a dye with a radioactive tracer into the region around the tumor. Blue dye and tracer will be drained through the sentinel or primary lymph node. This ensures identifying and surgical removing the sentinel node or group of nodes for further pathological examination (8). In the case of negative SLN, there is no need for removing the rest of the lymph nodes (15). Numerous studies and papers indicate that this procedure should become part of the standard management of early-stage cervical carcinoma.
The standard protocol for the treatment of patients with advanced cervical carcinoma includes cisplatin-based chemotherapy with paclitaxel (16). Unfortunately, most of them experience resistance to cisplatin and disease relapse. The new approach in the treatment of advanced cervical carcinoma is using of immune checkpoint inhibitors which block inhibitory receptors of immune system elements resulting in the activation of the anti-tumor response of immune cells (18). Few monoclonal antibodies are under observation for the targeted treatment of cervical carcinoma. Pembrolizumab (Keytruda) is a humanized monoclonal antibody against PD-1 (programmed cell death protein 1) allowed for treating the recurrent and metastatic cervical cancer and is given intravenously every three weeks (19, 20). Another potential PD-1 or PD-L1 targeted monoclonal antibodies that are in clinical trials are nivolumab (21, 22), atezolizumab (23), and durvalumab (24).
Additionally, molecular targeted therapy with anti-VEGF humanized antibody, bevacizumab, is being used in the treatment of the group of patients with advanced or recurrent cervical carcinoma (17). Binding to VEGF, bevacizumab inhibits vessel differentiation and endothelial cell proliferation (29). Angiogenesis, the process of the formation of a vascular network, seems to be very important for cervical cancer progression. HPV infection and hypoxia are associated with increased levels of VEGF, and the influence of the process of angiogenesis on tumor development is even higher in cervical carcinoma than in most solid tumors (25). Overexpression of VEGF is associated with progression and poor prognosis of cervical cancer (26), while the cytosol level of VEGF protein has been increased in tumor tissue in comparison to normal cervical tissue (25, 27, 28). Beside bevacizumab, other targeted drugs such as pazopanib, gefitinib, temsirolimus, cediranib, and nintedanib that block growth factors are under consideration for the treatment of advanced cervical cancer (25; 15).
Molecular diagnostic and laboratory testing have a key role in guiding the treatment in HPV-associated cancers. Infection with HPV leads to the accumulation of mutations and therefore to the silencing of the innate and adaptive antiviral immune response. In addition, the cells with incorporated viral genome lacking expression of target proteins that would be recognized by the host immune system are favored by selection (31). Since the HPV positive cervical cancer share similar mutation pattern, laboratory tests for detecting the mutations, epigenetic changes, and dysregulated HPV gene expression, would be of great importance for the prediction of the behavior of premalignant lesions. Also, liquid biopsy can be used for early detection or monitoring of cancer burden during treatment (30). Mutational analyses have the potential to identify mutations that can predict treatment response or give us important prognostic information (32). Therefore, next-generation sequencing has the potential to become a routine clinical laboratory test at the diagnosis in order to identify patient-specific mutations for monitoring tumor burden and predict risk. Additionally, sequencing can be very useful for predicting the aggressiveness of cervical precursor lesions (30). Beside diagnostic tests, HPV laboratory tests for the prevention of cervical carcinoma are developed. There are six molecular tests approved by FDA for screening programs: Qiagen Digene HC2 High-Risk HPV DNA assay, Hologic Cervista HPV HR assay, Hologic Cervista HPV 16/18, Roche Cobas HPV test, Hologic Aptima HPV, Hologic Aptima HPV 16 18/45 (33). Detecting HPV or its gene products in paraffin-embedded tissue is possible using the test such as HPV E6/E7 mRNA in situ hybridization, HPV DNA in situ hybridization, E6/E7 immunohistochemistry, HPV E6/E7 RT- PCR, or HPV DNA Q-PCR (34).
Molecular analyses and detection of the virus have great importance in the stratification of HPV positive patients at higher risk of disease progression. New diagnostic approaches must be considered for further improvements in guiding therapeutic interventions and preventing the progression of the disease.
- GLOBOCAN 2018, https:// gco.iarc.fr
- Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Heal. 2019;191–203.
- LaVigne AW, Triedman SA, Randall TC, Trimble EL, Viswanathan AN. Cervical cancer in low and middle income countries: Addressing barriers to radiotherapy delivery. Gynecol Oncol Reports. 2017;22(August):16–20.
- Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12-9.
- Reid R, Stanhope CR, Herschman BR, Booth E, Phibbs GD, Smith JP. Genital warts and cervical cancer. I. Evidence of an association between subclinical papillomavirus infection and cervical malignancy. Cancer. 1982 Jul 15;50(2):377-87.
- Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination – Review of Current Perspectives. J Oncol. 2019;2019.
- Virginia A. Screening for cervical cancer: U.S. Preventive services task force recommendation statement. Annals of Internal Medicine. 2012, vol. 156, pp. 880–890.
- Diab Y. Sentinel Lymph Nodes Mapping in Cervical Cancer a Comprehensive Review. Int J Gynecol Cancer. 2017;27(1):154–8.
- Cibula D, McCluggage WG. Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions. Gynecol Oncol. 2019;152(1):202–7.
- Cheng-Yen Lai J, Yang MS, Lu KW, Yu L, Liou WZ, Wang KL. The role of sentinel lymph node biopsy in early-stage cervical cancer: A systematic review. Taiwan J Obstet Gynecol. 2018;57(5):627–35.
- MacKay HT. In: Tierney LMJ, McPhee ST, Papadakis MA, editors. Gynecology in New York current medical diagnosis and treatment. New York: McGraw Hill. 2004. p. 701e2.
- Tobin MB, Lacey HJ, Meyer L, Mortimer PS. The psychological morbidity of breast cancer-related arm swelling. Psychological morbidity of lymphoedema. Cancer 1993;72:3248e52.
- Dostalek L, Åvall-Lundqvist E, Creutzberg CL, et al. ESGO Survey on Current Practice in the Management of Cervical Cancer International Journal of Gynecologic Cancer 2018;28:1226-1231.
- C.C. Network, Others, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Cervical Cancer. Version 1.2016, 2016.
- Baettig F, Vlajnic T, Vetter M, Glatz K, Hench J, Frank S, et al. Nivolumab in chemotherapy-resistant cervical cancer: Report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response. J Immunother Cancer. 2019;7(1):1–7.
- Tewari KS, Sill MW, Long HJ, 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. The New England journal of medicine. 2014;370(8):734-4
- Kanaan H, Kourie HR, Awada AH. Are virus-induced cancers more sensitive to checkpoint inhibitors? Future Oncol 2016;12(23):2665–8.
- Frenel J-S, Le Tourneau C, O’Neil BH, et al. Pembrolizumab in patients with advanced cervical squamous cell cancer: preliminary results from the phase Ib KEYNOTE-028 study. J Clin Oncol 2016;34(15 Suppl.):5515.
- Hollebecque A, Meyer T, Moore KN, Machiels J-PH, De Greve J, López-Picazo J. An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. J Clin Oncol 2017;35(15 Suppl.):5504.
- A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer, NCT02257528; 2017
- Phase 1b to assess the safety and tolerability of carboplatin-cyclophosphamide combined with atezolizumab, an antibody that targets programmed death ligand 1 (PD-L1), in patients with advanced breast cancer and gynaecologic cancer, NCT02914470; 2017
- Phase 1 study to evaluate the safety and tolerability of anti-PD-L1, MEDI4736, in combination with tremelimumab in subjects with advanced solid tumors, NCT01975831; 2017
- Tsuda N, Watari H, Ushijima K. Chemotherapy and molecular targeting therapy for recurrent cervical cancer. Chinese J Cancer Res. 2016;28(2):241–53.
- Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
- Cheng WF, Chen CA, Lee CN, et al. Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol 2000;96:721-6
- Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995;87:1237-45.
- Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
- Leal SM, Gulley ML. Current and Emerging Molecular Tests for Human Papillomavirus–Related Neoplasia in the Genomic Era. J Mol Diagnostics. 2017;19(3):366–77.
- Tang KW, Alaei-Mahabadi B, Samuelsson T, Lindh M, Larsson E: The landscape of viral expression and host gene fusion and adaptation in human cancer. Nat Commun 2013, 4:2513.
- Montgomery ND, Parker JS, Eberhard DA, Patel NM, Weck KE, Sharpless NE, Hu Z, Hayes DN, Gulley ML: Identification of human papillomavirus infection in cancer tissue by targeted next-generation sequencing. Appl Immunohistochem Mol Morphol 2016, 24: 490-495.
- Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE: Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011, 103:368e383
- Evans MF, Peng Z, Clark KM, Adamson CS, Ma XJ, Wu X, Wang H, Luo Y, Cooper K: HPV E6/E7 RNA in situ hybridization signal patterns as biomarkers of three-tier cervical intraepithelial neoplasia grade. PLoS One 2014, 9:e91142